Loading, Please Wait...

CST: 12/11/2019 02:15:19   

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

68 Days ago

LOS ANGELES, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between February 15, 2019 and August 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before October 18, 2019. 

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to comply with commonly accepted good manufacturing processes. Due to its poor practices, batches of the Company’s NKTR-214 immunotherapy were not uniform and differed from each other significantly. Because of the lack of uniformity, clinical tests on NKTR-214 varied based on the batch used. The Company’s PIVOT-02 study could not produce statistically significant data in support of NKTR-214 due to the variation between batches. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Nektar, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE:

The Schall Law Firm

Is your business listed correctly on America’s largest city directory network of 1,000 portals?